(4) Water treatment and dialysate
concentrates.
(A) Compliance required. A
facility shall meet the requirements of this section. A facility may follow
more stringent requirements than the minimum standards required by this
section.
(i) The facility administrator and
medical director shall each demonstrate responsibility for the water treatment
and dialysate supply systems to protect hemodialysis patients from adverse
effects arising from known chemical and microbial contaminates that may be
found in improperly prepared dialysate, to ensure that the dialysate is
correctly formulated and meets the requirements of all applicable quality
standards.
(ii) The facility
administrator and medical director must assure that policies and procedures
related to water treatment and dialysate are understandable and accessible to
the operator and that the training program includes quality testing, risks and
hazards of improperly prepared concentrate and bacterial issues.
(iii) The facility administrator and medical
director must be informed before any alteration of, or any device being added
to, the water system.
(B)
Water treatment. These requirements apply to water intended for use in the
delivery of hemodialysis, including the preparation of concentrates from powder
at a dialysis facility and dialysate.
(i) The
design for the water treatment system in a facility shall be based on
considerations of the source water for the facility and designed by a water
quality professional with education, training, or experience in dialysis system
design.
(ii) When a public water
system supply is not used by a facility, the source water shall be tested by
the facility at monthly intervals in the same manner as a public water system
as described in 30 TAC §
290.104(relating to Summary of
Maximum Contaminant Levels, Maximum Residual Disinfectant Levels, Treatment
Techniques, and Action Levels), and 30 TAC §
290.109(relating to Microbial
Contaminants) as adopted by the Texas Commission on Environmental Quality
(TCEQ).
(iii) The physical space in
which the water treatment system is located must be adequate to allow for
maintenance, testing, and repair of equipment. If mixing of dialysate is
performed in the same area, the physical space must also be adequate to house
and allow for the maintenance, testing, and repair of the mixing equipment and
for performing the mixing procedure.
(iv) The water treatment system components
shall be arranged and maintained so that bacterial and chemical contaminant
levels in the product water do not exceed the standards for hemodialysis water
quality described in §4.2.1 (concerning Water Bacteriology) and
§4.2.2 (concerning Maximum Level of Chemical Contaminants) of the American
National Standard, Water Treatment Equipment for Hemodialysis Applications,
August 2001 Edition, published by the Association for the Advancement of
Medical Instrumentation (AAMI).
(v)
Written policies and procedures for the operation of the water treatment system
must be developed and implemented. Parameters for the operation of each
component of the water treatment system must be developed in writing and known
to the operator. Each major water system component shall be labeled in a manner
that identifies the device; describes its function, how performance is verified
and actions to take in the event performance is not within an acceptable
range.
(vi) The materials of any
components of water treatment systems (including piping, storage, filters, and
distribution systems) that contact the purified water shall not interact
chemically or physically so as to affect the purity or quality of the product
water adversely. Such components shall be fabricated from unreactive materials
(e.g., plastics) or appropriate stainless steel. The use of materials that are
known to cause toxicity in hemodialysis, such as copper, brass, galvanized
material, or aluminum, is prohibited.
(vii) Chemicals infused into the water such
as iodine, acid, flocculants, and complexing agents shall be shown to be
nondialyzable or shall be adequately removed from product water. Monitors or
specific test procedures to verify removal of additives shall be provided and
documented.
(viii) Each water
treatment system shall include reverse osmosis membranes or deionization tanks
and a minimum of two carbon tanks in series. If the source water is from a
private supply which does not use chlorine/chloramine, the water treatment
system shall include reverse osmosis membranes or deionization tanks and a
minimum of one carbon tank.
(I) Reverse
osmosis membranes. Reverse osmosis membranes, if used, shall meet the standards
in §4.3.7 (concerning Reverse Osmosis) of the American National Standard,
Water Treatment Equipment for Hemodialysis Applications, August 2001 Edition,
published by the AAMI.
(II)
Deionization systems.
(-a-) Deionization
systems, if used, shall be monitored continuously to produce water of one
megohm-centimeter (cm) or greater specific resistivity (or conductivity of one
microsiemen/cm or less) at 25 degrees Celsius. An audible and visual alarm
shall be activated when the product water resistivity falls below this level
and the product water stream shall be prevented from reaching any point of
use.
(-b-) Patients shall not be
dialyzed on deionized water with a resistivity less than 1.0 megohm-cm measured
at the output of the deionizer.
(-c-) A minimum of two deionization (DI)
tanks in series shall be used with resistivity monitors including audible and
visual alarms placed pre and post the final DI tank in the system. The alarms
must be audible in the patient care area.
(-d-) Feed water for deionization systems
shall be pretreated with activated carbon adsorption, or a comparable
alternative, to prevent nitrosamine formation.
(-e-) If a deionization system is the last
process in a water treatment system, it shall be followed by an ultrafilter or
other bacteria and endotoxin reducing device.
(III) Carbon tanks.
(-a-) The carbon tanks must contain acid
washed carbon, 30-mesh or smaller with a minimum iodine number of
900.
(-b-) A minimum of two carbon
adsorption beds shall be installed in a series configuration.
(-c-) The total empty bed contact time (EBCT)
shall be at least ten minutes, with the final tank providing at least five
minutes EBCT. Carbon adsorption systems used to prepare water for portable
dialysis systems are exempt from the requirement for the second carbon and a
ten-minute EBCT if removal of chloramines to below 0.1 milligram (mg)/1 is
verified before each treatment.
(-d-) A means shall be provided to sample the
product water immediately prior to the final bed(s). Water from this port(s)
must be tested for chlorine/chloramine levels immediately prior to each patient
shift.
(-e-) All samples for
chlorine or chloramine testing must be drawn when the water treatment system
has been operating for at least 15 minutes.
(-f-) Tests for total chlorine, which include
both free and combined forms of chlorine, may be used as a single analysis with
the maximum allowable concentration of 0.1 mg/liter (L). Test results of
greater than 0.5 parts per million (ppm) for chlorine or 0.1 ppm for chloramine
from the port between the initial tank(s) and final tank(s) shall require
testing to be performed at the final exit and replacement of the initial
tank(s).
(-g-) In a system without a
holding tank, if test results at the exit of the final tank(s) are greater than
the parameters for chlorine or chloramine described in this subclause, dialysis
treatment shall be immediately terminated to protect patients from exposure to
chlorine or chloramine and the medical director shall be notified. In systems
with holding tanks, if the holding tank tests <1 mg/L for total chlorine,
the reverse osmosis (RO) may be turned off and the product water in the holding
tank may be used to finish treatments in process. The medical director shall be
notified.
(-h-) If means other than
granulated carbon are used to remove chlorine/chloramine, the facility's
governing body must approve such use in writing after review of the safety of
the intended method for use in hemodialysis applications. If such methods
include the use of additives, there must be evidence the product water does not
contain unsafe levels of these additives.
(ix) Water softeners, if used, shall be
tested at the end of the treatment day to verify their capacity to treat a
sufficient volume of water to supply the facility for the entire treatment day
and shall be fitted with a mechanism to prevent water containing the high
concentrations of sodium chloride used during regeneration from entering the
product water line during regeneration.
(x) If used, the face of a timer used to
control any component of the water treatment or dialysate delivery system shall
be visible to the operator at all times. Written evidence that timers are
checked for operation and accuracy each day of operation must be
maintained.
(xi) Filter housings,
if used during disinfectant procedures, shall include a means to clear the
lower portion of the housing of the disinfecting agents. Filter housings shall
be opaque.
(xii) Ultrafilters, or
other bacterial reducing filters, if used, shall be fitted with pressure gauges
on the inlet and outlet water lines to monitor the pressure drop across the
membrane. Ultrafilters shall be included in routine disinfection
procedures.
(xiii) If used, storage
tanks shall have a conical or bowl-shaped base and shall drain from the lowest
point of the base. Storage tanks shall have a tight-fitting lid and be vented
through a hydrophobic 0.2 micron air filter. Means shall be provided to
effectively disinfect any storage tank installed in a water distribution
system.
(xiv) Ultraviolet (UV)
lights, if used, shall be monitored at the frequency recommended by the
manufacturer. A log sheet shall be used to record monitoring.
(xv) Water treatment system piping shall be
labeled to indicate the contents of the pipe and direction of flow.
(xvi) The water treatment system must be
continuously monitored during patient treatment and be guarded by audible and
visual alarms which can be seen and heard in the dialysis treatment area should
water quality drop below specific parameters. Quality monitor sensing cells
shall be located as the last component of the water treatment system and at the
beginning of the distribution system. No water treatment components that could
affect the quality of the product water as measured by this device shall be
located after the sensing cell.
(xvii) When deionization tanks do not follow
a reverse osmosis system, parameters for the rejection rate of the membranes
must assure that the lowest rate accepted would provide product water in
compliance with §4.2.2 (concerning Maximum Level of Chemical Contaminants)
of the American National Standard, Water Treatment Equipment for Hemodialysis
Applications, August 2001 Edition published by the AAMI.
(xviii) A facility shall maintain written
logs of the operation of the water treatment system for each treatment day. The
log-book shall include each component's operating parameter and the action
taken when a component is not within the facility's set parameters.
(xix) Microbiological testing of product
water shall be conducted.
(I) Frequency.
Microbiological testing shall be conducted monthly and following any repair or
change to the water treatment system. For a newly installed water distribution
system, or when a change has been made to an existing system, weekly testing
shall be conducted for one month to verify that bacteria and endotoxin levels
are consistently within the allowed limits.
(II) Sample sites. At a minimum, sample sites
chosen for the testing shall include the beginning of the distribution piping,
at any site of dialysate mixing, and the end of the distribution
piping.
(III) Technique. Samples
shall be collected before sanitizing or disinfecting the water treatment system
and dialysis machines. Water testing results shall be routinely trended and
reviewed by the medical director to determine if results seem questionable or
if there is an opportunity for improvement. The medical director shall
determine if there is a need for retesting. Repeated results of "no growth"
shall be validated via an outside laboratory. A calibrated loop may not be used
in microbiological testing of water samples. Colonies shall be counted using a
magnifying device.
(IV) Expected
results. Product water used to prepare dialysate, concentrates from powder, or
to reprocess dialyzers for multiple use, shall contain a total viable microbial
count less than 200 colony forming units (CFU)/millimeter (ml) and an endotoxin
concentration less than 2 endotoxin units (EU)/ml. The action level for the
total viable microbial count in the product water shall be 50 CFU/ml and the
action level for the endotoxin concentration shall be 1 EU/ml.
(V) Required action for unacceptable results.
If the action levels described at subclause (IV) of this clause are observed in
the product water, corrective measures shall be taken promptly to reduce the
levels into an acceptable range.
(VI) Records. All bacteria and endotoxin
results shall be recorded on a log sheet to identify trends that may indicate
the need for corrective action.
(xx) If ozone generators are used to
disinfect any portion of the water or dialysate delivery system, testing based
on the manufacturer's direction shall be used to measure the ozone
concentration each time disinfection is performed, to include testing for safe
levels of residual ozone at the end of the disinfection cycle. Testing for
ozone in the ambient air shall be conducted on a periodic basis as recommended
by the manufacturer. Records of all testing must be maintained in a
log.
(xxi) If used, hot water
disinfection systems shall be monitored for temperature and time of exposure to
hot water as specified by the manufacturer. Temperature of the water shall be
recorded at a point furthest from the water heater, where the lowest water
temperature is likely to occur. The water temperature shall be measured each
time a disinfection cycle is performed. A record that verifies successful
completion of the heat disinfection shall be maintained.
(xxii) After chemical disinfection, means
shall be provided to restore the equipment and the system in which it is
installed to a safe condition relative to residual disinfectant before the
product water being used for dialysis applications.
(xxiii) Samples of product water must be
submitted for chemical analysis every six months and must demonstrate that the
quality of the product water used to prepare dialysate or concentrates from
powder, meets §4.2.2 (concerning Maximum Level of Chemical Contaminants)
of the American National Standard, Water Treatment Equipment for Hemodialysis
Applications, August 2001 Edition, published by the AAMI.
(I) Samples for chemical analysis shall be
collected at the end of the water treatment components and at the most distal
point in each water distribution loop, if applicable. All other outlets from
the distribution loops shall be inspected to ensure that the outlets are
fabricated from compatible materials. Appropriate containers and pH adjustments
shall be used to ensure accurate determinations. New facilities or facilities
that add or change the configuration of the water distribution system must draw
samples at the most distal point for each water distribution loop, if
applicable, on a one-time basis.
(II) Additional chemical analysis shall be
submitted if substantial changes are made to the water treatment system or if
the percent rejection of a reverse osmosis system decreased 5.0 percent or more
from the percent rejection measured at the time the water sample for the
preceding chemical analysis was taken.
(xxiv) Facility records must include all test
results and evidence that the medical director has reviewed the results of the
water quality testing and directed corrective action when indicated.
(xxv) Only persons qualified by the education
or experience may operate, repair, or replace components of the water treatment
system.
(C) Dialysate.
(i) Quality control procedures shall be
established to ensure ongoing conformance to policies and procedures regarding
dialysate quality.
(ii) Each
facility shall set all hemodialysis machines to use only one family of
concentrates. When new machines are put into service or the concentrate family
or concentrate manufacturer is changed, samples shall be sent to a laboratory
for verification.
(iii) Before each
patient treatment, staff shall verify the dialysate conductivity and pH of each
machine with an independent device.
(iv) Bacteriological testing shall be
conducted.
(I) Frequency. Responsible
facility staff shall develop a schedule to ensure each hemodialysis machine is
tested quarterly for bacterial growth and the presence of endotoxins.
Hemodialysis machines of home patients shall be cultured monthly until results
not exceeding 200 CFU/ml are obtained for three consecutive months, then
quarterly samples shall be cultured.
(II) Acceptable limits. Dialysate shall
contain less than 200 CFU/ml and an endotoxin concentration of less than 2
EU/ml. The action level for total viable microbial count shall be 50 CFU/ml and
the action level for endotoxin concentration shall be 1 EU/ml.
(III) Action to be taken. Disinfection and
retesting shall be done when bacterial or endotoxin counts exceed the action
levels. Additional samples shall be collected when there is a clinical
indication of a pyrogenic reaction and/or septicemia.
(v) Only a licensed nurse may use an additive
to increase concentrations of specific electrolytes in the acid concentrate.
Mixing procedures shall be followed as specified by the additive manufacturer.
When additives are prescribed for a specific patient, the container holding the
prescribed acid concentrate shall be labeled with the name of the patient, the
final concentration of the added electrolyte, the date the prescribed
concentrate was made, and the name of the person who mixed the
additive.
(vi) All components used
in concentrate preparation systems (including mixing and storage tanks, pumps,
valves, and piping) shall be fabricated from materials (e.g., plastics or
appropriate stainless steel) that do not interact chemically or physically with
the concentrate so as to affect its purity, or with the germicides used to
disinfect the equipment. The use of materials that are known to cause toxicity
in hemodialysis such as copper, brass, galvanized material, and aluminum is
prohibited.
(vii) Facility policies
shall address means to protect stored acid concentrates from tampering or from
degeneration due to exposure to extreme heat or cold.
(viii) Procedures to control the transfer of
acid concentrates from the delivery container to the storage tank and prevent
the inadvertent mixing of different concentrate formulations shall be
developed, implemented, and enforced. The storage tanks shall be clearly
labeled.
(ix) Concentrate mixing
systems shall include a purified water source, a suitable drain, and a ground
fault protected electrical outlet.
(I)
Operators of mixing systems shall use personal protective equipment as
specified by the manufacturer during all mixing processes.
(II) The manufacturer's instructions for use
of a concentrate mixing system shall be followed, including instructions for
mixing the powder with the correct amount of water. The number of bags or
weight of powder added shall be determined and recorded.
(III) The mixing tank shall be clearly
labeled to indicate the fill and final volumes required to correctly dilute the
powder.
(IV) Systems for preparing
either bicarbonate or acid concentrate from powder shall be monitored according
to the manufacturer's instructions.
(V) Concentrates shall not be used, or
transferred to holding tanks or distribution systems, until all tests are
completed.
(VI) If a facility
designs its own system for mixing concentrates, procedures shall be developed
and validated using an independent laboratory to ensure proper
mixing.
(x) Acid
concentrate mixing tanks shall be designed to allow the inside of the tank to
be rinsed when changing concentrate formulas.
(I) Acid mixing systems shall be designed and
maintained to prevent rust and corrosion.
(II) Acid concentrate mixing tanks shall be
emptied completely and rinsed with product water before mixing another batch of
concentrate to prevent cross contamination between different batches.
(III) Acid concentrate mixing equipment shall
be disinfected as specified by the equipment manufacturer or in the case where
no specifications are given, as defined by facility policy.
(IV) Records of disinfection and rinsing of
disinfectants to safe residual levels shall be maintained.
(xi) Bicarbonate concentrate mixing tanks
shall have conical or bowl-shaped bottoms and shall drain from the lowest point
of the base. The tank design shall allow all internal surfaces to be
disinfected and rinsed.
(I) Bicarbonate
concentrate mixing tanks shall not be prefilled the night before use.
(II) If disinfectant remains in the mixing
tank overnight, this solution must be completely drained, the tank rinsed and
tested for residual disinfectant before preparing the first batch of that day
of bicarbonate concentrate.
(III)
Unused portions of bicarbonate concentrate shall not be mixed with fresh
concentrate.
(IV) At a minimum,
bicarbonate distribution systems shall be disinfected weekly. More frequent
disinfection shall be done if required by the manufacturer, or if dialysate
culture results are above the action level.
(V) If jugs are reused to deliver bicarbonate
concentrate to individual hemodialysis machines:
(-a-) jugs shall be emptied of concentrate,
rinsed and inverted to drain at the end of each treatment day;
(-b-) at a minimum, jugs shall be disinfected
weekly, more frequent disinfection shall be considered by the medical director
if dialysate culture results are above the action level; and
(-c-) following disinfection, jugs shall be
drained, rinsed free of residual disinfectant, and inverted to dry and testing
for residual disinfectant shall be done and documented.
(xii) All mixing tanks, bulk
storage tanks, dispensing tanks and containers for single hemodialysis
treatments shall be labeled as to the contents.
(I) Mixing tanks. Before batch preparation, a
label shall be affixed to the mixing tank that includes the date of preparation
and the chemical composition or formulation of the concentrate being prepared.
This labeling shall remain on the mixing tank until the tank has been
emptied.
(II) Bulk storage or
dispensing tanks. These tanks shall be permanently labeled to identify the
chemical composition or formulation of their contents.
(III) Single machine containers. At a
minimum, single machine containers shall be labeled with sufficient information
to differentiate the contents from other concentrate formulations used in the
facility and permit positive identification by users of container
contents.
(xiii)
Permanent records of batches produced shall be maintained to include the
concentrate formula produced, the volume of the batch, lot numbers of powdered
concentrate packages, the manufacturer of the powdered concentrate, date and
time of mixing, test results, person performing mixing, and expiration date (if
applicable).
(xiv) If dialysate
concentrates are prepared in the facility, the manufacturers' recommendations
shall be followed regarding any preventive maintenance. Records shall be
maintained indicating the date, time, person performing the procedure, and the
results (if applicable).